Fukuda, M., Yamaguchi, H., Mukae, H., & Ashizawa, K. (2018). Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer. J Thorac Dis.
Stile di citazione ChicagoFukuda, Minoru, Hiroyuki Yamaguchi, Hiroshi Mukae, e Kazuto Ashizawa. "Programmed Death Ligand-1 Inhibitors Potentially Carry a Lower Risk of Pneumonitis Compared With Programmed Death-1 Inhibitors in Patients With Non-small Cell Lung Cancer." J Thorac Dis 2018.
Citazione MLAFukuda, Minoru, Hiroyuki Yamaguchi, Hiroshi Mukae, e Kazuto Ashizawa. "Programmed Death Ligand-1 Inhibitors Potentially Carry a Lower Risk of Pneumonitis Compared With Programmed Death-1 Inhibitors in Patients With Non-small Cell Lung Cancer." J Thorac Dis 2018.